FDA Expands GSK RSV Vaccine Use to At-Risk Adults Ages 18–49
PHILADELPHIA, PA — GSK plc (NYSE: GSK) said the U.S. Food and Drug Administration has expanded approval of its RSV vaccine AREXVY to include adults ages 18 to 49 who …
FDA Expands GSK RSV Vaccine Use to At-Risk Adults Ages 18–49 Read More